Redox regulation, protein S-nitrosylation, and synapse loss in Alzheimer's and related dementias
- PMID: 39515322
- PMCID: PMC11624102
- DOI: 10.1016/j.neuron.2024.10.013
Redox regulation, protein S-nitrosylation, and synapse loss in Alzheimer's and related dementias
Abstract
Redox-mediated posttranslational modification, as exemplified by protein S-nitrosylation, modulates protein activity and function in both health and disease. Here, we review recent findings that show how normal aging, infection/inflammation, trauma, environmental toxins, and diseases associated with protein aggregation can each trigger excessive nitrosative stress, resulting in aberrant protein S-nitrosylation and hence dysfunctional protein networks. These redox reactions contribute to the etiology of multiple neurodegenerative disorders as well as systemic diseases. In the CNS, aberrant S-nitrosylation reactions of single proteins or, in many cases, interconnected networks of proteins lead to dysfunctional pathways affecting endoplasmic reticulum (ER) stress, inflammatory signaling, autophagy/mitophagy, the ubiquitin-proteasome system, transcriptional and enzymatic machinery, and mitochondrial metabolism. Aberrant protein S-nitrosylation and transnitrosylation (transfer of nitric oxide [NO]-related species from one protein to another) trigger protein aggregation, neuronal bioenergetic compromise, and microglial phagocytosis, all of which contribute to the synapse loss that underlies cognitive decline in Alzheimer's disease and related dementias.
Keywords: Alzheimer’s disease; Lewy body dementia; cognitive decline; neurodegenerative disorders; nitric oxide; protein S-nitrosylation; synapse loss; transnitrosylation.
Copyright © 2024 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests S.A.L. discloses that he is an inventor on worldwide patents for the use of memantine and NitroSynapsin for neurodegenerative and neurodevelopmental disorders. Per Harvard University guidelines, he participates in a royalty-sharing agreement with his former institution, Boston Children’s Hospital/Harvard Medical School, which licensed the FDA-approved drug memantine (Namenda) to Forest Laboratories, Inc./Actavis/Allergan/AbbVie. S.A.L. is also a scientific founder of Adamas Pharmaceuticals, Inc. (now owned by Supernus Pharmaceuticals, Inc.), which developed or comarkets FDA-approved forms of memantine- or amantadine-containing drugs (NamendaXR, Namzaric, and GoCovri), and of EuMentis Therapeutics, Inc., which has licensed NitroSynapsin and related aminoadamantane nitrates from S.A.L. T.N. serves as a consultant to Dojindo Molecular Technologies, and S.A.L. serves on the Scientific Advisory Board of Point 6 Bio, Ltd.
References
Publication types
MeSH terms
Substances
Grants and funding
- R01 AG061845/AG/NIA NIH HHS/United States
- R35 AG071734/AG/NIA NIH HHS/United States
- R01 AG078756/AG/NIA NIH HHS/United States
- R01 AG077046/AG/NIA NIH HHS/United States
- RF1 NS123298/NS/NINDS NIH HHS/United States
- DP1 DA041722/DA/NIDA NIH HHS/United States
- U01 AG088679/AG/NIA NIH HHS/United States
- R56 AG065372/AG/NIA NIH HHS/United States
- R61 NS122098/NS/NINDS NIH HHS/United States
- R01 AG056259/AG/NIA NIH HHS/United States
- R01 NS123298/NS/NINDS NIH HHS/United States
- R01 DA048882/DA/NIDA NIH HHS/United States
- RF1 AG057409/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical